Cargando…

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

BACKGROUND: Several proteins that promote angiogenesis are overexpressed in hepatocellular carcinoma (HCC) and have been implicated in disease pathogenesis. Sunitinib has antiangiogenic activity and is an oral multitargeted inhibitor of vascular endothelial growth factor receptors (VEGFRs)-1, -2, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harmon, Charles S, DePrimo, Samuel E, Raymond, Eric, Cheng, Ann-Lii, Boucher, Eveline, Douillard, Jean-Yves, Lim, Ho Y, Kim, Jun S, Lechuga, Maria José, Lanzalone, Silvana, Lin, Xun, Faivre, Sandrine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162912/ https://www.ncbi.nlm.nih.gov/pubmed/21787417 http://dx.doi.org/10.1186/1479-5876-9-120

Ejemplares similares

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
por: Keyvanjah, Kiana, et al.
Publicado: (2012)

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
por: Harmon, Charles S., et al.
Publicado: (2013)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
por: DePrimo, Samuel E, et al.
Publicado: (2007)

Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors
por: Wiedmann, Marcus W., et al.
Publicado: (2012)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
por: Bouattour, Mohamed, et al.
Publicado: (2018)

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
por: Le Tourneau, Christophe, et al.
Publicado: (2007)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
por: Mizuno, Kazuyuki, et al.
Publicado: (2023)

Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy
por: Sahani, Dushyant V, et al.
Publicado: (2013)

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
por: Ito, Tetsuhide, et al.
Publicado: (2013)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
por: Zhao, Dongxu, et al.
Publicado: (2023)

Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
por: Wu, Jia-Lin, et al.
Publicado: (2023)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial
por: Chauhan, Nikhil, et al.
Publicado: (2018)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
por: Salem, Riad, et al.
Publicado: (2021)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Systemic treatment for unresectable hepatocellular carcinoma
por: Leowattana, Wattana, et al.
Publicado: (2023)

Osteonecrosis of the Jaws in Patient Received Bisphosphonates and Sunitinib Separately: A Case Report
por: Ashrafi, Farzaneh, et al.
Publicado: (2017)

Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
por: Kang, Xindan, et al.
Publicado: (2023)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
por: Stacchiotti, Silvia, et al.
Publicado: (2012)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
por: Okusaka, Takuji, et al.
Publicado: (2021)

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
por: Tullemans, Bibian M. E., et al.
Publicado: (2022)

Y-90 Microshperes in the Treatment of Unresectable Hepatocellular Carcinoma
por: Al-Kalbani, Abdullah, et al.
Publicado: (2008)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Cellular based treatment modalities for unresectable hepatocellular carcinoma
por: Damiris, Konstantinos, et al.
Publicado: (2021)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
por: Kumar, Shashank, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rhmbec4s407oss1crh17r49v3s